These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8089053)

  • 1. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.
    MacGowan AP; White LO; Brown NM; Lovering AM; McMullin CM; Reeves DS
    J Antimicrob Chemother; 1994 May; 33(5):1051-4. PubMed ID: 8089053
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosage adjustment of antiinfective therapy in patients with renal impairment.
    Eckhardt A; Borner K; Keller F; Zellner D
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):99-102. PubMed ID: 9088997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous ciprofloxacin dosing in a morbidly obese patient.
    Caldwell JB; Nilsen AK
    Ann Pharmacother; 1994 Jun; 28(6):806. PubMed ID: 7919576
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.
    Jones EM; McMullin CM; Hedges AJ; Lovering AM; White LO; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1997 Jul; 40(1):121-4. PubMed ID: 9249215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.
    Gous A; Lipman J; Scribante J; Tshukutsoane S; Hon H; Pinder M; Mathivha R; Verhoef L; Stass H
    Int J Antimicrob Agents; 2005 Jul; 26(1):50-5. PubMed ID: 15955670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofloxacin in combined renal and hepatic impairment.
    Fraise AP; Smith SP
    J Antimicrob Chemother; 1990 Feb; 25(2):297-8. PubMed ID: 2329106
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of renal function on the bioavailability of ciprofloxacin.
    Plaisance KI; Drusano GL; Forrest A; Weir MR; Standiford HC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1031-4. PubMed ID: 2393263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of ciprofloxacin per os in treatment of serious infections.
    Dellamonica P; Bernard E; Etesse H; Garraffo R; Beziau H
    Chemioterapia; 1987 Jun; 6(2 Suppl):391-4. PubMed ID: 3509456
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
    Bassaris HP; Chrysanthopoulos CJ; Skouelis AT; Starakis JC
    J Chemother; 1989 Jul; 1(4 Suppl):676-7. PubMed ID: 16312588
    [No Abstract]   [Full Text] [Related]  

  • 13. [The treatment of gastrointestinal infections with ciprofloxacin].
    Ippolito A; La Gioia G; Matarrese M; Resta F; Angelini P; Ruffo F
    Minerva Med; 1991 Apr; 82(4):181-7. PubMed ID: 2017314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavobacterium meningosepticum infection, in a 32-day-old child on acute peritoneal dialysis, treated with ciprofloxacin.
    Humphreys H; Lovering A; White LO; Williams EW
    J Antimicrob Chemother; 1989 Feb; 23(2):292-4. PubMed ID: 2496073
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of ciprofloxacin in biliary sepsis.
    Chrysanthopoulos CJ; Skoutelis AT; Starakis JC; Arvaniti A; Bassaris HP
    Infection; 1988; 16(4):249. PubMed ID: 3182091
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serum elimination of HES in moderately reduced renal function].
    Schimetta W; Kröll W; Pölz W; Colombo T; Gassmayr SE; Sirtl C; List WF
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Aug; 37(8):468-74. PubMed ID: 12165916
    [No Abstract]   [Full Text] [Related]  

  • 17. Ciprofloxacin treatment of acute infections in immunocompromised host.
    Nemes G; Heuser Y; Stolle D; Piroth HD; Nemes P
    J Chemother; 1989 Jul; 1(4 Suppl):722-3. PubMed ID: 16312607
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral ciprofloxacin for treatment of severe infections.
    Lobo IM; Silva NF; Assef MC; Mangini C; Silva ML; Bortoletto ML; Mendonça JS; Levi GC
    Int J Clin Pharmacol Res; 1993; 13(2):81-5. PubMed ID: 8354593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ciprofloxacin by the intravenous route in the treatment of respiratory infections].
    Mangiarotti P; Manara G; Bianchi L; Piccioni PD; Grassi C
    G Ital Chemioter; 1989; 36(1-3):89-94. PubMed ID: 2488917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.